XML 61 R48.htm IDEA: XBRL DOCUMENT
v3.26.1

Intangibles, Net and Goodwill - Schedule of Rollforward of Intangible Assets (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2026 | Jun. 30, 2025 | Jun. 30, 2026 | Jun. 30, 2025
Finite-lived Intangible Assets [Roll Forward] |  |  |  |
Beginning balance |  |  | $ 97,651 | $ 58,652
Additions |  |  | 0 | 0
Amortization | $ (2,081) | $ (1,263) | (4,162) | (2,526)
Ending balance | 93,489 | 56,126 | 93,489 | 56,126
Acquired ARIKAYCE R&D |  |  |  |
Finite-lived Intangible Assets [Roll Forward] |  |  |  |
Beginning balance |  |  | 23,038 | 27,888
Additions |  |  | 0 | 0
Amortization |  |  | (2,425) | (2,425)
Ending balance | 20,613 | 25,463 | 20,613 | 25,463
Licensing Agreements |  |  |  |
Finite-lived Intangible Assets [Roll Forward] |  |  |  |
Beginning balance |  |  |  | 1,164
Additions |  |  |  | 0
Amortization |  |  |  | (101)
Ending balance |  | 1,063 |  | 1,063
Licensing Agreements | PARI milestones |  |  |  |
Finite-lived Intangible Assets [Roll Forward] |  |  |  |
Beginning balance |  |  | 962 |
Additions |  |  | 0 |
Amortization |  |  | (101) |
Ending balance | 861 |  | 861 |
Licensing Agreements | AstraZeneca milestones |  |  |  |
Finite-lived Intangible Assets [Roll Forward] |  |  |  |
Beginning balance |  |  | 44,051 |
Additions |  |  | 0 |
Amortization |  |  | (1,636) |
Ending balance | 42,415 |  | 42,415 |
Acquired IPR&D |  |  |  |
Finite-lived Intangible Assets [Roll Forward] |  |  |  |
Beginning balance |  |  | 29,600 | 29,600
Additions |  |  | 0 | 0
Amortization |  |  | 0 | 0
Ending balance | $ 29,600 | $ 29,600 | $ 29,600 | $ 29,600

X
- Definition Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482558/350-40-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 55 -Paragraph 40 -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsRollForward
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in finite-lived intangible asset acquired in business combination, asset acquisition, and from joint venture formation. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 805 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478072/944-805-50-1 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=insm_AcquiredResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=insm_PARIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=insm_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |